Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?

Hims & Hers (HIMS), a telehealth platform focused on direct-to-consumer medication sales, is experiencing significant growth, with its stock up 118% year-to-date and projecting $6.5 billion in revenue by 2030. The company's success stems from circumventing the traditional insurance market and offering affordable medications, recently expanding into weight loss drugs through a partnership with Novo Nordisk and acquiring European competitor Zava to broaden its reach. While the company faces regulatory risks, analysts project substantial long-term profitability, estimating a potential $1.5 billion in bottom-line profits and free cash flow by 2030.

Analysis

Hims & Hers (NYSE: HIMS) is demonstrating significant traction in disrupting the U.S. healthcare market through its direct-to-consumer telehealth platform, which bypasses traditional insurance channels, a strategy contributing to its current 2.4 million active customers. The company's stock performance, up 118% year-to-date and 446% over the last five years, reflects strong investor confidence in its model, which focuses on affordable medications in areas like sexual health, dermatology, hair loss, mental health, and now weight loss. HIMS projects substantial revenue growth, aiming for $6.5 billion by 2030, an increase from a projected $2 billion in 2025 and reported $1.4 billion in 2024, where weight loss drugs contributed $200 million. A strategic partnership with Novo Nordisk, announced at the end of April, allows Hims & Hers to sell Wegovy directly, resolving previous uncertainties in its weight loss segment that arose after the shortage of Wegovy ended and compounding pharmacy exceptions were no longer applicable. Further expansion is evidenced by the recent intent to acquire European competitor Zava, which is expected to add 1.3 million active customers across the U.K., Germany, France, and Ireland. The company maintains an impressive gross profit margin of 77%, supporting analyst projections of a net profit margin exceeding 20% and potential bottom-line profits of $1.5 billion by 2030. Despite a current market capitalization of $12.3 billion, the stock is presented as potentially undervalued if 2030 earnings targets are met, although a history of navigating regulatory environments described as "fast and loose" introduces a notable risk factor.

Key Decisions for Investors

• Given Hims & Hers' robust revenue growth projections to $6.5 billion by 2030, strategic partnerships like the one with Novo Nordisk, and international expansion via the Zava acquisition, growth-oriented investors might find the stock's long-term potential compelling, especially considering its current $12.3 billion market cap against future profit estimates.
• Investors should closely monitor the execution of its weight loss drug strategy post-Novo Nordisk partnership and the successful integration of Zava, as these are critical catalysts for achieving its ambitious revenue and profitability targets, including a projected $1.5 billion in bottom-line profits by 2030.
• The primary non-market risk highlighted is regulatory compliance, stemming from past instances of operating in legally ambiguous areas; therefore, ongoing vigilance regarding the company's adherence to healthcare laws and regulations is crucial, as any missteps could significantly impact its reputation and valuation.